Susceptibility testing of Cryptococcus diffluens against amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole and posaconazole

References

• Available from < www.cbs.knaw.nl>
   Google Scholar
• Sugita T, Takashima M, Ikeda R, Nakase T, Shinoda T. Intraspecies diversity of Cryptococcus albidus isolated from humans as revealed by sequences of the internal transcribed spacer regions. Microbiol Immunol 2001; 45: 291–297
   PubMed Web of Science ®Google Scholar
• Kantarcioglu AS, Boekhout T, de Hoog GS, et al. Subcutaneous cryptococcosis due to Cryptococcus diffluens in a patient with sporotrichoid lesions: case report, features of the case isolate and in vitro antifungal susceptibilities. Med Mycol 2007; 45: 173–181
   PubMedGoogle Scholar
• Pfaller MA, Messer SA, Boyken L, , et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp and Cryptococcus neoformans collected during 200l and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 2004; 48: 201–205.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Zhang J, Messer SA, et al. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob Agents Chemother 1999; 43: 169–171
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Boyken L, et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol 2005; 43: 2163–2167
   PubMed Web of Science ®Google Scholar
• Hoban DJ, Zhanel GG, Karlowsky JA. In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients. Antimicrob. Agents Chemother 1999; 43: 1463–1464
   PubMed Web of Science ®Google Scholar
• Yildiran S T, Fothergill AW, Sutton DA, Rinaldi MG. In vitro susceptibilities of cerebrospinal fluid isolates of Cryptococcus neoformans collected during a ten-year period against fluconazole, voriconazole and posaconazole (SCH56592). Mycoses 2002; 45: 378–383
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Mycol 2003; 20: 121–136
   PubMedGoogle Scholar
• Perfect JR, Cox GM, Dodge RK, Schell WA. In vitro and in vivo efficacies of the azole SCH 56592 against Cryptococcus neoformans. Antimicrob Agents Chemother 1996; 40: 1910–1913
   PubMed Web of Science ®Google Scholar
• Perkins A, Gomez-Lopez A, Mellado E, Rodriguez-Tudela JL, Cuenca-Estrella M. Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans. J Antimicrob Chemother 2005; 56: 1144–1147
   PubMed Web of Science ®Google Scholar
• Chryssanthou E, Cuenca-Estrella M. Comparison of the antifungal susceptibility testing subcommittee of the European Committee on Antibiotic Susceptibility Testing Proposed Standard and the E—test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species. J Clin Microbiol 2002; 40: 3841–3844
   PubMed Web of Science ®Google Scholar
• Aller AI, Martin-Mazuelos E, Gutiérrez MJ, et al. Comparison of the Etest and microdilution method for antifungal susceptibility testing of Cryptococcus neoformans to four antifungal agents. J Antimicrob Chemother 2000; 46: 997–1000
   PubMed Web of Science ®Google Scholar
• Viviani MA, Esposto MC, Cogliati M, Tortorano AM. Flucytosine and cryptococcosis: which in vitro test is the best predictor of outcome?. J Chemother 2003; 15: 124–128
   PubMed Web of Science ®Google Scholar
• National Committee for Clinical Laboratory Standards Reference Method for Broth Dilution Antifungal Susceptibility Testing for Yeasts. Approved Standard; 2nd ed; Document M27-A2 National Committee for Laboratory Standards. Wayne, PA, 2002.
   Google Scholar
• Rodriguez-Tudela JL, Martin-Diez F, Cuenca-Estrella M, et al. Influence of shaking on antifungal susceptibility testing of Cryptococcus neoformans: a comparison of the NCCLS standard M27-A medium, buffered yeast nitrogen base, and RPMI-2% glucose. Antimicrob Agents Chemother 2000; 44: 400–404
   PubMedGoogle Scholar
• Hawser SP, Norris H, Jessup CJ, Ghannoum MA. Comparison of a 2,3-Bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl-2H-tetrazolium hydroxide] (XTT) colorimetric method with the standadized National Committee for Clinical Laboratory Standards method of testing clinical yeast isolates for susceptibility to antifungal agents. J Clin Microbiology 1998; 36: 1450–1452
   PubMed Web of Science ®Google Scholar
• Paull DK, Shoemaker H, Boyd MR. The synthesis of XTT: a new tetrazolium reagent that is bioreducible to a water-soluble formazan. J Heterocycl Chem 1998; 25: 911–914
   Google Scholar
• Tellier R, Krajden M, Grigoriew GA, Campbell I. Innovative endpoint determination system for antifungal susceptibility testing of yeasts. Antimicrob Agents Chemother 1992; 36: 1619–1625
   PubMed Web of Science ®Google Scholar
• Lozano-Chiu M, Paetznick VL, Ghannoum MA, Rex JH. Detection of resistance to amphotericin B among Cryptococcus neoformans isolates: performance of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M-27A methodologies. J Clin Microbiol 1998; 36: 2817–2822
   PubMed Web of Science ®Google Scholar
• Rex JH, Pfaller MA, Wash TJ, , et al. Antifungal susceptibility testing: practical aspects and current challenges. 2001; 14: 643–658.
   Google Scholar
• Souza LK, Fernandes O, de F, Kobayashi CC, et al. Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiania city, Goias, Brazil. Rev Inst Med Trop Sao Paulo 2005; 47: 253–256
   PubMedGoogle Scholar
• Matar MJ, Ostrosky-Zeichner L, et al. Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole. Antimicrob Agents Chemother 2003; 47: 1647–1651
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Hollis RJ, Jones RN. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3.685 clinical isolates of Candida spp and Cryptococcus neoformans. Antimicrobial Agents Chemother 2001; 45: 2862–2864
   PubMed Web of Science ®Google Scholar
• Vandenbossche I, Vaneechoutte M, Vandevenne M, De Baere T, Verschraegen G. Susceptibility testing of fluconazole by the NCCLS broth macrodilution method, Etest, and disk diffusion for application in the routine laboratory. J Clin Microbiol 2002; 40: 918–921
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Coffmann S. Comparison of visual and spectrophotometric methods of MIC endpoint determinations by using broth microdilution methods to test five antifungal agents, including the new triazol D0870. J Clin Microbiol 1995; 33: 1094–1097
   PubMed Web of Science ®Google Scholar
• Barchiesi F, Del Poeta M, Morbiducci V, Ancarani F, Scalise G. Turbidimetric and visual criteria for determining the in vitro activity of six antifungal agents against Candida spp. and Cryptococcus neoformans. Mycopathologia 1993; 124: 19–25
   PubMedGoogle Scholar
• Anaissie E, Paetznick V, Bodey GP. Fluconazole susceptibility testing of Candida albicans: microtiter method that is independent of inoculum size, temperature, and time of reading. Antimicrob Agents Chemother 1991; 35: 1641–1646
   PubMed Web of Science ®Google Scholar
• Meletiadis J, Mouton JW, Meis JFGM, et al. Comparison of spectrophotometric and visual readings of NCCLS method and evaluation of a colorimetric method based on reduction of a soluble tetrazolium salt, 2,3-Bis (2-Methoxy-4-nitro-5[(sulfenylamino)carbonyl]-2H-tetrazolium-hydroxide), for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol 2001; 39: 4256–4263
   PubMed Web of Science ®Google Scholar
• Wanock DW, Johnson EM. Rogers TRF on behalf of the BSAC, Working Party on Antifungal Chemotherapy. Multicenter evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. J Antimicrob Chemother 1998; 42: 321–331
   PubMedGoogle Scholar
• Johnson EM. Issues in antifungal susceptibility testing. J Antimicrob Chemother 2008; 61(Suppl. 1)i13–i18
   PubMedGoogle Scholar
• Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000; 30: 710–718
   PubMed Web of Science ®Google Scholar
• Powderly WG, Saag MS, Cloud GA, et al. A controlled trial of fluconazole or amphotericin B to prevent relaps of cryptococcal meningitis in patients with the acquired immunodefficiency syndrome. N Engl J Med 1992; 326: 793–798
   PubMed Web of Science ®Google Scholar
• Khan ZU, Randhawa HS, Kowshik T, Chowdhary A, Chandy R. Antifungal susceptibility of Cryptococcus neoformans and Cryptococcus gattii isolates from decayed wood of trunk hollows of Ficus religiosa and Syzygium cumini trees in north-western India. J Antimicrob Chemother 2007; 60: 312–316
   PubMed Web of Science ®Google Scholar
• Berg J, Clancy CJ, Nguyen MH. The hidden danger of primary fluconazole prophylaxis for patients with AIDS. Clin Infect Dis 1998; 26: 186–187
   PubMed Web of Science ®Google Scholar
• Brandt ME, Pfaller MA, Hajjeh MA, et al. Trends in antifungal drug susceptibilty of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998. Antimicrob Agents Chemother 2001; 45: 3065–3069
   PubMedGoogle Scholar
• Kantarcioglu AS, Yücel A. A flucytosine resistant Cryptococcus neoformans (serotype D) strain isolated in Turkey from cutaneous lesions. Med Mycol 2002; 40: 519–523
   PubMedGoogle Scholar
• Rex J, Pfaller M, Galgiani J, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conseptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997; 24: 235–247
   PubMed Web of Science ®Google Scholar
• D'Souza CA, Heitman J. It infects me, it infects me not: phenotypic switching in the fungal pathogen Cryptococcus neoformans. J Clin Invest 2001; 108: 1577–1578
   PubMedGoogle Scholar
• Fries BC, Taborda CP, Serfass E, Casadeval A. Phenotypic switching of Cryptococcus neoformans occurs in vivo and influences the outcome of infection. J Clin Invest 2001; 108: 1639–1648
   PubMed Web of Science ®Google Scholar
• Fries BC, Cook E, Wang X, Casadevall A. Effects of antifungal interventions on the outcome of experimental infections with phenotypic switch variants of Cryptococcus neoformans. Antimicrob Agents Chemother 2005; 49: 350–357
   PubMedGoogle Scholar
• Jain N, Li L, McFadden DC, et al. Phenotypic switching in Cryptococcus neoformans variety gattii strain is associated with changes in virulence and promotes dissemination to the central nervous system. Infect Immun 2006; 74: 896–903
   PubMed Web of Science ®Google Scholar
• Petraitene R, Petraitis V, Groll AH, et al. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: corelation with galactomannan antigenemia. Antimicrob Agents Chemother 2001; 45: 857–869
   PubMedGoogle Scholar
• Sabo JA, Abdel-Rahman SM. Voriconazole: a new triazole antifungal. Ann Pharmacoter 2000; 34: 1032–1043
   PubMed Web of Science ®Google Scholar
• Groll AH, Kolve H. Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy. Eur J Clin Microbiol Infect Dis 2004; 23: 256–270
   PubMed Web of Science ®Google Scholar